Related Experiment Video
Updated: Jul 26, 2025

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
Does health technology assessment compromise access to pharmaceuticals?
Melanie Büssgen1, Tom Stargardt2
1Hamburg Center for Health Economics, University of Hamburg, Hamburg, Germany. melanie.buessgen@uni-hamburg.de.
Germany's health technology assessment (HTA) regulation slowed the decrease in pharmaceutical launch delays but improved drug availability. Policymakers can use this to balance cost savings and patient access.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Regulatory Science
Background:
- Rising pharmaceutical costs have led to the implementation of health technology assessment (HTA) systems globally.
- HTA is often considered a 'fourth hurdle' in pharmaceutical market access.
- Germany introduced its HTA system, AMNOG, in 2011 to manage drug costs and access.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Regulation
Biopharmaceutics and Pharmacokinetics: Overview

